Transocean stock today nudges higher in premarket after Australia drilling update

Transocean stock today nudges higher in premarket after Australia drilling update

NEW YORK, December 31, 2025, 08:57 ET — Premarket

  • Transocean shares were fractionally higher ahead of the open after closing Tuesday at $4.13.
  • A drilling update in Australia kept attention on offshore activity and potential follow-on work.
  • Oil prices were steady but on track for their biggest annual drop since 2020, a key read-through for drillers.

Transocean Ltd shares (RIG) were up 0.2% in premarket trading on Wednesday at $4.14 after closing at $4.13 in the previous session. The offshore driller is trading near the top of its 52-week range and has a market value of about $4.55 billion. Google

The move matters because offshore drillers sit downstream of oil-company budgets, and year-end price signals often shape spending plans for the next cycle. Investors tend to treat small-cap drillers as a high-beta bet on whether crude prices can stabilize and keep multi-year projects moving.

Oil prices were little changed on Wednesday, with Brent at $61.54 a barrel and U.S. West Texas Intermediate at $58.16, but both benchmarks were headed for losses of more than 15% in 2025 on oversupply concerns, Reuters reported. BNP Paribas commodities analyst Jason Ying expects Brent to dip to $55 a barrel in the first quarter before recovering to $60 for the rest of 2026, and traders are watching U.S. government inventory data due later Wednesday and an OPEC+ meeting on Jan. 4. Reuters

In Australia, ConocoPhillips paused drilling at the Charlemont-1 exploration well after the well intersected unexpected gas shows while using Transocean’s Transocean Equinox rig, joint venture partner 3D Energi said in an operational update. “The Essington-1 well is the first discovery in the Otway since 2021 and is a promising start to ConocoPhillips’ exploration activities in the region,” Jan-Arne Johansen, president of ConocoPhillips Australia, said after the earlier find. OE Digital

For Transocean, activity like this matters because drillers earn a dayrate — a daily fee — for the rig and crew. Extra wells can translate into more work and, over time, add to backlog, the contracted revenue a driller expects to collect.

Still, drilling pauses and design reviews can cut both ways in the near term. They can delay progress on a campaign, but they also underscore that operators are pushing forward on exploration even with crude prices under pressure.

Offshore drillers often trade as a group, with investors comparing utilization and dayrates across peers such as Valaris and Noble. Contract wins and fleet updates tend to move the stocks more than single-well headlines once the market opens.

Macro data also stayed in focus before the bell after U.S. jobless claims fell to 199,000 for the week ended Dec. 27, the Labor Department said, a signal that the labor market remains resilient heading into 2026. AP News

That backdrop matters for energy shares because labor-market strength can influence rate expectations and the dollar, both of which feed into commodity pricing. Oil is typically priced in dollars, so a stronger greenback can weigh on crude.

In the near term, traders will be watching the U.S. Energy Information Administration’s inventory report later Wednesday and any headlines out of OPEC+ ahead of its Jan. 4 meeting. Updates on whether Charlemont-1 resumes drilling could also shape sentiment around offshore activity in Australia.

The next clear company catalyst is earnings. Nasdaq’s earnings calendar currently estimates Transocean will report around mid-February, though the company has not yet confirmed a date. Nasdaq

Stock Market Today

  • Vanda's tradipitant wins FDA nod for motion sickness; VNDA stock jumps after-hours
    December 31, 2025, 9:38 AM EST. Vanda Pharmaceuticals' candidate tradipitant has received FDA approval to prevent vomiting from motion sickness, under the brand Nereus. The decision follows three clinical studies, including two phase III real-world trials conducted at sea named Motion Syros and Motion Serifos, backing the therapy's efficacy. VNDA shares rose about 18% in after-hours trade and extended gains in pre-market trading. Vanda licensed tradipitant from Eli Lilly and is exploring its use in gastroparesis and for nausea linked to GLP-1 receptor agonists in obesity and diabetes therapies. Separately, the company operates under a collaborative framework with the FDA to resolve disputes around Hetlioz and tradipitant, with an expedited re-review extended to Dec 5, 2025.
Snap stock dips before the open after CEO Evan Spiegel files to sell 1.26 million shares
Previous Story

Snap stock dips before the open after CEO Evan Spiegel files to sell 1.26 million shares

B2Gold stock today: BTG flat in premarket as gold slips on year-end profit-taking
Next Story

B2Gold stock today: BTG flat in premarket as gold slips on year-end profit-taking

Go toTop